clinical trial · NCT07242248
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
Inflammatory Bowel DiseaseColitis, UlcerativeCrohn's Disease
brief summary
The purpose of this study is to evaluate the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the outcomes of treatment (clinical outcomes) in adult participants with moderately to severely active Ulcerative Colitis (UC) or Crohn's Disease (CD) under real-world settings. CD and UC are the main type of Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.
started
Nov 17, 2025
primary completion
Mar 5, 2029
completion
Mar 17, 2029
last updated
Apr 13, 2026
official title
Real World Observation of Guselkumab Treatment in Patients With Ulcerative Colitis and Crohn's Disease - a Study of Treatment Outcomes in the UK
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol